Aklonil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aklonil

Property Description
Active ingredient Clonazepam (INN)
Form Conventional Oral Tablet; Orally Disintegrating Tablet (ODT)
Pharmacological class Benzodiazepine Anticonvulsant, Anxiolytic
General purpose To stabilize the nervous system and reduce excessive electrical activity
Origin Synthetic (1,4-benzodiazepine derivative)

What Type of Medicine is Aklonil? (Definition and Classification)

Aklonil is a prescription-only pharmaceutical preparation containing the active chemical substance Clonazepam, which is the International Nonproprietary Name (INN) for the compound. It is fundamentally classified as a benzodiazepine, falling into the therapeutic classes of a Benzodiazepine Anticonvulsant and an Anxiolytic. This classification defines the medicine's role in the management of conditions involving neuronal overactivity and anxiety.

The substance, Clonazepam, is a synthetic 1,4-benzodiazepine derivative, distinguished by its high-potency and long-acting profile compared to other analogues within its class. This long therapeutic duration is a differentiating factor that supports sustained control for patients. As a potent CNS depressant medicine and a GABAergic agent, its primary role is to modulate and dampen electrical signaling in the central nervous system, establishing its use in providing generalized relief from states of neurological excitement.

Composition and General Purpose

Aklonil is supplied for the oral route as a single-ingredient product, containing only Clonazepam. The medication is available both as a conventional tablet and an orally disintegrating tablet (ODT). The ODT form represents a key formulation distinction, as it dissolves rapidly upon contact with saliva.

The general purpose of the medicine is rooted in its ability to enhance the inhibitory effects of γ-aminobutyric acid (GABA), the brain's major inhibitory neurotransmitter. This enhancement helps suppress abnormal electrical signaling and reduce neuronal excitability, conferring the medication with its core anticonvulsant and anxiolytic properties. Clonazepam helps achieve a stabilizing effect by regulating chemical signaling in the brain, which is the mechanism used to manage typical scenarios such as panic disorder.

Regulatory References

  1. Clonazepam: MedlinePlus Drug Information

What side effects are possible with Aklonil?

Aklonil (Clonazepam) is associated with adverse reactions that are primarily linked to its effects as a Central Nervous System (CNS) depressant, which is the basis for its official safety profile documented by regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse effects listed as common in clinical trials—defined as occurring in one percent or more of patients—include somnolence (drowsiness), dizziness, ataxia (impaired coordination), dysarthria (slurred speech), depression, memory disturbance, and intellectual ability reduced. Less frequent postmarketing reports, classified with an incidence not known, have included confusion, increased appetite, and increased hair growth.

Serious Safety Risks and Contraindications

Regulatory documents emphasize several serious risks, including a Boxed Warning regarding the combined use of Aklonil with opioids, which may result in profound sedation, respiratory depression, coma, and death. The medicine carries warnings for the potential for abuse, misuse, addiction, and the development of physical dependence. Abrupt discontinuation can lead to life-threatening acute withdrawal reactions.

Safety constraints dictate that Aklonil is contraindicated (should not be used) in patients with a history of sensitivity to benzodiazepines or with clinical or biochemical evidence of significant liver disease. The risks of dependence and withdrawal are officially noted to increase with longer treatment duration and higher daily dose. For older adults, the label notes they may be more susceptible to CNS depressant effects such as confusion and severe drowsiness.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Aklonil, containing the active substance Clonazepam, is a documented medical scenario primarily resulting in an exaggeration of the central nervous system (CNS) depressant effects. Regulatory bodies define the official profile based on the severity of this CNS depression, which dictates the mandatory emergency response.

Documented Overdose Manifestations
Common Symptoms Drowsiness, confusion, slurred speech (dysarthria), impaired coordination (ataxia), and reduced reflexes (hyporeflexia).
Severe Outcomes Profound CNS depression, respiratory depression, significant hypotension, and coma. Death is possible, particularly when Aklonil is taken in combination with other central nervous system depressants.
Emergency Actions and Considerations
Action Mandate Immediate medical attention must be sought for any suspected overdose. Emergency medical services must be contacted immediately if the individual has trouble breathing, has collapsed, or is unresponsive.
Antidote Note The specific benzodiazepine antagonist, Flumazenil, may be used by a healthcare professional. However, official regulatory warnings note that Flumazenil administration carries a risk of precipitating seizures in patients who are physically dependent on Clonazepam.
Management Focus Management is primarily symptomatic and supportive, requiring the maintenance of a patent airway and continuous monitoring of vital signs (respiratory and cardiovascular status).
Specific Risk The official labeling highlights a specific risk of severe outcomes, including death, from co-ingestion with other CNS depressants such as opioids or alcohol. The elderly population may also be more vulnerable to profound CNS effects.

Therapeutic Uses of Aklonil

What Aklonil Treats: Main Uses and Benefits

Management of Seizure Disorders and Epileptic Symptoms

This medication is commonly used for the management of conditions characterized by periods of heightened symptoms related to recurrent seizures and symptoms of increased neurological or muscular activity. Its use is relevant for specific forms of epilepsy, including Lennox-Gastaut syndrome, myoclonic seizures, akinetic seizures, and certain types of absence seizures. Aklonil is applied in addressing symptoms that interfere with daily functioning (such as uncontrolled muscle jerking or brief episodes of unresponsiveness). The therapeutic role contributes to easing the overall symptom load and may assist with the frequency and intensity of fits.


Symptomatic Relief for Panic Disorder

The medicine is also considered relevant in clinical settings marked by acute and recurrent states of intense fear, specifically for the management of panic disorder with or without agoraphobia. It may assist with managing symptom clusters that may become intense or disruptive, such as a rapid heartbeat, sweating, trembling, and the acute feeling of distress associated with these attacks. Aklonil generally provides supportive relief that assists with maintaining functional stability during these phases of heightened tension.


Quick Fact: Relief for Heightened Symptoms
Common Scenarios: Often used during phases of increased distress, applied in addressing conditions presenting with acute or episodic manifestations, and when symptoms become temporarily overwhelming.
Patient Benefit: Provides supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with difficult episodes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Aklonil?

The official eligibility profile for Aklonil (Clonazepam) is defined by regulatory bodies based on age, underlying conditions, and physiological status.

Absolute Contraindications

The medicine is strictly contraindicated and must not be used by patients with a known hypersensitivity to Clonazepam or any other benzodiazepine. Use is also prohibited for individuals with acute narrow-angle glaucoma, severe liver disease, or severe respiratory depression (including sleep apnoea syndrome). Patients in a coma or those with a history of drug or alcohol abuse are also excluded from use under European labeling.

Restricted and Conditional Use

Eligibility is restricted for several populations. Older adults (ge 65 years) require caution and should initiate treatment at the lowest dosage due to increased sensitivity. Patients with renal impairment or mild to moderate hepatic impairment must also use the medicine with caution.

Age and Reproductive Status

For pediatric patients, Aklonil is approved for specific seizure disorders; however, its use for panic disorder in those under 18 years is not established. Due to potential risks, use during pregnancy is generally restricted, and the medicine is not recommended for individuals who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Aklonil (Clonazepam) as defined in government regulatory labeling.


Pharmacodynamic and Contraindicated Combinations

Interactions that produce additive central nervous system (CNS) depression are a primary concern. The co-administration of Aklonil with Opioids carries a formal Boxed Warning in the US regulatory labeling due to the risk of profound sedation, respiratory depression, coma, and death. Use with Alcohol (Ethanol) is formally advised to be avoided for the same reason. Furthermore, Aklonil is Contraindicated in patients with Significant Liver Disease because impaired hepatic metabolism may reduce drug elimination, leading to potential accumulation.


Pharmacokinetic Interactions (Exposure Modification)

The elimination of Clonazepam is subject to hepatic metabolism, primarily involving the CYP3A4 enzyme system, which can result in exposure-altering pharmacokinetic interactions:

  • CYP3A4 Inducers: Strong inducers such as Phenytoin or Carbamazepine are documented to reduce the plasma concentration of Clonazepam.
  • CYP3A4 Inhibitors: Strong inhibitors, including Ketoconazole or Itraconazole, are documented to increase the serum concentration of Clonazepam.

The co-administration of Valproic Acid and Clonazepam is specifically documented to potentially produce absence status (a form of seizure activity). No known interactions with non-alcoholic food or drinks are documented in the regulatory labeling.

Mechanism of Action

Selective Inhibition of ASK1 Kinase

Aklonil functions as a highly selective inhibitor of Apoptosis signal-regulating kinase 1 (ASK1), an enzyme that regulates the cell's response to various stress stimuli. By binding to and deactivating this specific target, Aklonil initiates an immediate molecular intervention that attenuates signaling transmission through the ASK1 pathway.


Attenuation of Cellular Stress Pathways

The primary mechanistic action of Aklonil blocks the activation of the JNK and p38 Mitogen-Activated Protein Kinase (MAPK) pathways, which are the main downstream components of the ASK1 cascade. The resulting attenuation limits the transcription of pro-inflammatory and pro-apoptotic genes.


️ Modulation of Cell Fate and Inflammation

The modulation of the ASK1 axis results in two core biological effects: cytoprotection (cell survival) and an anti-inflammatory effect. By reducing stress-induced cell death and limiting the release of inflammatory mediators (like TNFalpha), the mechanistic activity influences the balance of cellular function by reducing apoptosis and limiting inflammatory signaling.

Dosage and Administration Information

How to Use Aklonil: Official Administration Guidelines

Aklonil (clonazepam) is administered via the oral route, available as a conventional tablet (often scored for dose division) and an orally disintegrating tablet (ODT). The general use pattern is structured around low starting doses, gradual dose titration, and controlled discontinuation.

Dosing and Titration Schedules

Indication Starting Dose Maximum Dose Limit
Seizure Disorders (Adults) 1.5 mg/day (divided into multiple doses) 20 mg/day
Panic Disorder (Adults) 0.25 mg (taken twice daily) 4 mg/day

Treatment initiation requires a low dose with gradual increases, typically by 0.5 mg to 1 mg every three days until the maintenance level is achieved.

Administration Logistics and Special Instructions

The medicine may be taken with or without food. The total daily dose is initially divided, but once stabilized, the largest dose is typically given at bedtime if doses are unequal. For the ODT formulation, it must be handled with dry hands and allowed to dissolve on the tongue before swallowing.

Population and Discontinuation Rules

Dosing is adjusted for specific populations. For older adults (65 years), a lower initial dose, generally not exceeding 0.5 mg/day, is required. Dosage for children is weight-based. Treatment must not be stopped abruptly. Standard guidelines describe a slow, controlled taper, with the dose decreased by no more than 0.125 mg every three days until the medicine is completely withdrawn.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aklonil


Evidence for Use in Specific Seizure Disorders

Research has examined Aklonil's study in conditions characterized by fluctuating or episodic manifestations, particularly in specific forms of epilepsy. The evidence base consists of older clinical trials, as well as uncontrolled observational studies and case series, often where the medicine was observed in patients already taking other anti-seizure medications (used as an add-on or "adjunctive" therapy).

Studies primarily focused on adults and children presenting with myoclonic, akinetic, and specific absence seizures. Researchers monitored outcomes related to episodic or acute changes, specifically measuring the frequency and intensity of seizure events. Findings describe patterns observed in the studies regarding a change in seizure activity across the populations examined. Regulatory summaries indicate that a loss of effect was observed in some studies within approximately three months of use. Overall, the available evidence base for this use is classified as moderate.


Evidence for Use in Panic Disorder


The research informing the study of Aklonil in panic disorder is primarily derived from short-term, randomized, double-blind, placebo-controlled trials (RCTs). Studies focused on adult outpatients diagnosed with panic disorder, including those also experiencing agoraphobia.

In these trials, researchers examined outcomes reflecting episodic or acute changes related to panic attacks. They monitored and measured the change in the frequency of panic attacks and used standard scales to assess overall symptom intensity or variability. The short-term trials, typically lasting 6 to 9 weeks, described the findings related to the outcomes measured between the medicine groups and the placebo groups.


Research Gaps and Areas of Uncertainty


Controlled data on long-term outcomes for both indications are limited. For seizure disorders, follow-up durations were limited in many studies, and the documentation of tolerance (a gradual loss of effect) was observed in some studies, suggesting that the durability of the initial findings needs further clarification.

Regarding panic disorder, the primary research gap involves limited controlled data for long-term outcomes; regulatory reviews state that controlled research for use beyond the initial nine-week period has not been systematically conducted. Research also notes the existence of research gaps regarding optimal discontinuation methods. These limitations collectively highlight what is known — and what is still uncertain — about Aklonil.

Frequently Asked Questions (FAQ)

Common questions about Aklonil (FAQ)


Q: How quickly does Aklonil start to work?

Official product information states that the medicine's active substance typically reaches its peak concentration in the bloodstream within one to four hours after oral administration. This rapid absorption contributes to the substance's presence in the system shortly after administration.


Q: If I miss a dose of Aklonil, what generally happens?

Regulatory guidance for a missed dose advises patients to take the medication as soon as it is remembered. However, if it is almost time for the next scheduled dose, official instructions recommend skipping the missed one entirely. Official patient information indicates that doses should not be doubled.


Q: Are there any specific foods or drinks that should be avoided when taking Aklonil?

According to official administration guidelines, the medicine may be taken with or without food. However, regulatory labeling strongly advises against consuming alcohol while using Aklonil. This is due to the documented risk of additive central nervous system (CNS) depressant effects.


Q: Can older adults generally take Aklonil?

Official labeling describes conditions for use in older adults (generally those aged 65 years and older) and notes that specific caution is required. Regulatory instructions indicate the use of a lower initial dosage due to an increased susceptibility to central nervous system depressant effects, such as confusion and severe drowsiness.


Q: What happens if I stop taking Aklonil suddenly?

Regulatory documents include warnings that abrupt discontinuation is associated with the risk of serious and potentially life-threatening acute withdrawal reactions. These reactions may include symptoms such as irritability, nausea, tremor, and seizures. Official instructions mandate a slow, controlled taper of the dose when the medicine is being withdrawn.


Q: What if I forget to take my Aklonil with food, as instructed?

Official administration guidelines state that the medicine may be taken with or without food, meaning its action is generally not dependent on food consumption. Based on official guidelines, the timing relative to food intake is not noted to substantially impact the drug's action.


Q: Why must Aklonil be stored in a specific way?

The medicine requires specific storage conditions, including being kept at a controlled room temperature, protected from light and moisture, to help maintain its stability. Furthermore, regulatory guidelines require it to be stored in a safe and secured place and kept out of the reach of children due to its classification as a controlled substance.


Q: Is Aklonil known to be habit-forming or addictive?

Regulatory documents contain warnings about the potential for abuse, misuse, and addiction. The official labeling states that the medicine may be habit-forming and can lead to the development of physical or psychological dependence. Official information states that the risks associated with dependence and withdrawal may be higher with longer treatment duration and higher daily doses.


Q: What is the typical duration of treatment with Aklonil?

The required duration of treatment varies depending on the medical condition being managed. For seizure disorders, the evidence base includes examinations of long-term use. For other indications, studies often examine short-term outcomes, and official regulatory guidance notes the need for regular patient review to assess the continued necessity of the medication.


Q: How long does Aklonil stay in your system after the last dose?

The active substance has a relatively long half-life, which is the time it takes for half of the dose to be eliminated from the body. Regulatory documents state this half-life is typically 30 to 40 hours. While the main effects subside, traces of the drug's metabolites may remain detectable in the body for a number of days following the last dose.


Q: Is it safer to take Aklonil in the morning or evening?

Official instructions for administration indicate that once a patient is on a stable maintenance dose, the entire daily amount can often be taken as a single dose in the evening. If the total daily dose is unequal, regulatory guidance advises that the largest portion should be given at bedtime. This instruction is provided in the official administration documents.


Q: Can I take Aklonil if I am breastfeeding?

Official regulatory labeling describes the use during breastfeeding as not recommended for individuals who are breastfeeding. It is noted that the active substance passes into breast milk in small amounts, and regulatory documents advise monitoring the infant for potential signs of drowsiness or difficulty feeding.


Q: Does Aklonil interact with caffeine?

Official information indicates a possible pharmacodynamic interaction with caffeine and other central nervous system stimulants. This interaction is noted in regulatory information to potentially reduce the sedative effects of the medicine, especially when the medication is being used for conditions involving sleep.


Q: Is Aklonil available generically?

Yes, the active ingredient in Aklonil, known as clonazepam, is widely available in a lower-cost generic formulation. This availability is confirmed in drug approval records from regulatory bodies.


Q: How long does it take for Aklonil's benefits to become noticeable?

While the medicine is absorbed relatively quickly (reaching peak concentration in 1–4 hours), the time it takes for the full therapeutic effect to be noted can vary. Achieving therapeutic stability for chronic conditions often involves a period of gradual dose adjustment (titration) which can span several weeks.


Q: What are the legal status and classifications of Aklonil?

Aklonil is designated as a prescription-only drug by regulatory authorities. It is further classified as a Schedule IV controlled substance under federal regulation, a classification given due to its recognized potential for abuse, misuse, and dependence.

How should Aklonil be stored and disposed of?

How to Store and Dispose of Aklonil (Clonazepam)

Storage Conditions

Aklonil tablets must be stored at controlled room temperature, specifically between 20 C and 25 C. The medicine must be kept in a tightly closed container and protected from both light and moisture to maintain stability. The official labeling requires the product to be kept in a safe place and strictly out of the reach and sight of children due to its classification as a controlled substance. Storage in damp areas, such as the bathroom, is prohibited.

Disposal Instructions

For unused or expired Aklonil, the official guidance recommends using a community drug take-back program or an authorized collector. If this is not available, the medicine should be mixed with an undesirable substance (e.g., dirt, coffee grounds) in a sealed container and discarded with household trash. The tablets must not be flushed into wastewater or sewers.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aklonil found in:

A-Z Index: